Skip to content

Clinical Study on Guihuang Prescription in Treating Type III Prostatitis (damp heat and blood stasis syndrome)

Clinical Study on Guihuang Prescription in Treating Type III Prostatitis (damp heat and blood stasis syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047920
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-06-24
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic prostatitis

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-50 years; ?? 2. Those who meet the diagnostic criteria of type III prostatitis in Western medicine; 3. TCM syndrome differentiation in line with damp-heat stasis syndrome; 4. The disease course exceeds 3 months; 5. Those who have not received other treatments before treatment, those who have received treatment should stop taking the drug for at least 2 weeks; 6. Those who signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic constitution, those who are allergic to this drug and those who cannot tolerate the drug; 2. Combined with urethritis, acute prostatitis, urinary calculi, urethral stricture, prostate tumor and other diseases; 3. Patients with severe cardiovascular disease, cerebrovascular disease, hypotension, liver and kidney insufficiency, hematopoietic system disease, and mental illness.

Design outcomes

Primary

MeasureTime frame
National Institutes of Health Chronic Prostatitis Symptom Index Score;

Countries

China

Contacts

Public ContactGao Qinghe

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

gaoqinghe1949@126.com+86 10 62835134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026